{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:41:51Z","timestamp":1793943711860,"version":"4.8.0"},"reference-count":54,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2018,10,1]]},"DOI":"10.1001\/jamaoncol.2018.2961","type":"journal-article","created":{"date-parts":[[2018,8,9]],"date-time":"2018-08-09T17:59:00Z","timestamp":1533837540000},"page":"1389","source":"Crossref","is-referenced-by-count":83,"title":["Maintenance Treatment and Survival in Patients With Myeloma"],"prefix":"10.1001","volume":"4","author":[{"given":"Francesca","family":"Gay","sequence":"first","affiliation":[{"name":"Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Citt\u00e0 della Salute e della Scienza di Torino, Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Jackson","sequence":"additional","affiliation":[{"name":"Newcastle upon Tyne Hospitals Trust, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Rosi\u00f1ol","sequence":"additional","affiliation":[{"name":"Hematology Department, IDIBAPS, Hospital Clinic, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A.","family":"Holstein","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Nebraska Medical Center, Omaha"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[{"name":"Hematology Department, University Hospital H\u00f4tel-Dieu, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Spada","sequence":"additional","affiliation":[{"name":"Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Citt\u00e0 della Salute e della Scienza di Torino, Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faith","family":"Davies","sequence":"additional","affiliation":[{"name":"The Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jos\u00e9","family":"Lahuerta","sequence":"additional","affiliation":[{"name":"Hospital Universitario 12 de Octubre, Madrid, Spain. PETHEMA\/Grupo Espa\u00f1ol de Mieloma"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[{"name":"H\u00e9matologie and Inserm CIC 1082, Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Bringhen","sequence":"additional","affiliation":[{"name":"Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Citt\u00e0 della Salute e della Scienza di Torino, Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Evangelista","sequence":"additional","affiliation":[{"name":"Unit of Clinical Epidemiology, Azienda Ospedaliero-Universitaria Citt\u00e0 della Salute e della Scienza di Torino and CPO Piemonte, Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Hulin","sequence":"additional","affiliation":[{"name":"Service d\u2019H\u00e9matologie, H\u00f4pital Haut-L\u00e9v\u00eaque, CHU Bordeaux, 33600 Pessac, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"Panzani","sequence":"additional","affiliation":[{"name":"Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Citt\u00e0 della Salute e della Scienza di Torino, Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Cairns","sequence":"additional","affiliation":[{"name":"Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Di Raimondo","sequence":"additional","affiliation":[{"name":"Division of Hematology, AOU Policlinico-OVE, University of Catania, Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Macro","sequence":"additional","affiliation":[{"name":"Institut d'H\u00e9matologie de Basse Normandie, University Hospital of Caen, C\u00f4te de Nacre, 14033 Caen Cedex 9, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Marina","family":"Liberati","sequence":"additional","affiliation":[{"name":"Universit\u00e0 degli Studi di Perugia, Struttura Complessa Universitaria Oncoematologia - Azienda Ospedaliera Santa Maria di Terni, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Pawlyn","sequence":"additional","affiliation":[{"name":"The Institute of Cancer Research, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Offidani","sequence":"additional","affiliation":[{"name":"Clinica di Ematologia, AOU Ospedali Riuniti di Ancona, Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Spencer","sequence":"additional","affiliation":[{"name":"Department of Haematology, Alfred Health-Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"H\u00e1jek","sequence":"additional","affiliation":[{"name":"Department of Haematooncology, University Hospital Ostrava, Czech Republic and Faculty of Medicine, University of Ostrava, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth J.","family":"Morgan","sequence":"additional","affiliation":[{"name":"The Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Blad\u00e9","sequence":"additional","affiliation":[{"name":"Hematology Department, IDIBAPS, Hospital Clinic, Barcelona, Spain"},{"name":"Hematology Department, IDIBAPS, Hospital Clinic, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Sonneveld","sequence":"additional","affiliation":[{"name":"Department of Hematology, Erasmus Medical Center, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"San-Miguel","sequence":"additional","affiliation":[{"name":"Cl\u00ednica Universidad de Navarra-CIMA, IDISNA, CIBERONC, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip L.","family":"McCarthy","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplant Program, Department of Medicine, Roswell Park Comprehensive Cancer Center, State University at Buffalo, Buffalo, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Ludwig","sequence":"additional","affiliation":[{"name":"Wilhelminen Cancer Research Institute, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Boccadoro","sequence":"additional","affiliation":[{"name":"Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Citt\u00e0 della Salute e della Scienza di Torino, Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Victoria","family":"Mateos","sequence":"additional","affiliation":[{"name":"University Hospital of Salamanca-Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Attal","sequence":"additional","affiliation":[{"name":"Department of Hematology, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9513","key":"coi180059r1","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","article-title":"Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.","volume":"367","author":"Palumbo","year":"2006","journal-title":"Lancet"},{"issue":"9","key":"coi180059r2","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1182\/blood-2009-08-237974","article-title":"Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma.","volume":"116","author":"Waage","year":"2010","journal-title":"Blood"},{"issue":"9594","key":"coi180059r3","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","article-title":"Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.","volume":"370","author":"Facon","year":"2007","journal-title":"Lancet"},{"issue":"1","key":"coi180059r4","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/ejh.2010.86.issue-1","article-title":"Addition of thalidomide to oral melphalan\/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group.","volume":"86","author":"Beksac","year":"2011","journal-title":"Eur J Haematol"},{"issue":"19","key":"coi180059r5","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.1200\/JCO.2009.26.1610","article-title":"Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study.","volume":"28","author":"Wijermans","year":"2010","journal-title":"J Clin Oncol"},{"issue":"22","key":"coi180059r6","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1200\/JCO.2008.21.0948","article-title":"Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01\/01 trial.","volume":"27","author":"Hulin","year":"2009","journal-title":"J Clin Oncol"},{"issue":"8","key":"coi180059r7","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.1182\/blood-2008-03-145235","article-title":"Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities.","volume":"112","author":"Barlogie","year":"2008","journal-title":"Blood"},{"issue":"11","key":"coi180059r8","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1200\/JCO.2008.18.8573","article-title":"Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure.","volume":"27","author":"Spencer","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9","key":"coi180059r9","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1182\/blood-2012-09-451872","article-title":"A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial.","volume":"121","author":"Stewart","year":"2013","journal-title":"Blood"},{"issue":"10","key":"coi180059r10","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1182\/blood-2006-05-022962","article-title":"Maintenance therapy with thalidomide improves survival in patients with multiple myeloma.","volume":"108","author":"Attal","year":"2006","journal-title":"Blood"},{"issue":"24","key":"coi180059r11","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","article-title":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/ GMMG-HD4 trial.","volume":"30","author":"Sonneveld","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"coi180059r12","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/leu.2017.211","article-title":"Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65\/GMMG-HD4 trial.","volume":"32","author":"Goldschmidt","year":"2018","journal-title":"Leukemia"},{"issue":"9","key":"coi180059r13","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1038\/leu.2017.35","article-title":"Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA\/GEM trial.","volume":"31","author":"Rosi\u00f1ol","year":"2017","journal-title":"Leukemia"},{"issue":"7","key":"coi180059r14","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1200\/JCO.2013.52.0023","article-title":"Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.","volume":"32","author":"Palumbo","year":"2014","journal-title":"J Clin Oncol"},{"issue":"34","key":"coi180059r15","doi-asserted-by":"publisher","first-page":"5101","DOI":"10.1200\/JCO.2010.29.8216","article-title":"Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.","volume":"28","author":"Palumbo","year":"2010","journal-title":"J Clin Oncol"},{"issue":"10","key":"coi180059r16","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/S1470-2045(10)70187-X","article-title":"Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.","volume":"11","author":"Mateos","year":"2010","journal-title":"Lancet Oncol"},{"issue":"12","key":"coi180059r17","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1182\/blood-2014-05-573733","article-title":"GEM2005 trial update comparing VMP\/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?","volume":"124","author":"Mateos","year":"2014","journal-title":"Blood"},{"issue":"29","key":"coi180059r18","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.","volume":"35","author":"McCarthy","year":"2017","journal-title":"J Clin Oncol"},{"key":"coi180059r19","article-title":"Lenalidomide maintenance significantly improves outcomes compared to observation irrespective of cytogenetic risk: results of the Myeloma XI trial.","volume":"130","author":"Jackson","year":"2017","journal-title":"Blood"},{"issue":"15","key":"coi180059r20","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma.","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"issue":"18","key":"coi180059r21","doi-asserted-by":"publisher","first-page":"4696","DOI":"10.1182\/blood-2010-10-300970","article-title":"Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.","volume":"117","author":"Munshi","year":"2011","journal-title":"Blood"},{"issue":"11","key":"coi180059r22","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations.","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"coi180059r24","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials.","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"coi180059r25","doi-asserted-by":"publisher","first-page":"d2304","DOI":"10.1136\/bmj.d2304","article-title":"How to obtain the P value from a confidence interval.","volume":"343","author":"Altman","year":"2011","journal-title":"BMJ"},{"issue":"2","key":"coi180059r26","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies.","volume":"3","author":"Higgins","year":"2012","journal-title":"Res Synth Methods"},{"issue":"9","key":"coi180059r27","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.3324\/haematol.2009.020586","article-title":"Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma.","volume":"95","author":"Ludwig","year":"2010","journal-title":"Haematologica"},{"issue":"1","key":"coi180059r28","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2011-06-357038","article-title":"The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis.","volume":"119","author":"Morgan","year":"2012","journal-title":"Blood"},{"issue":"21","key":"coi180059r29","doi-asserted-by":"publisher","first-page":"6030","DOI":"10.1158\/1078-0432.CCR-12-3211","article-title":"Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatment.","volume":"19","author":"Morgan","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"19","key":"coi180059r30","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma.","volume":"366","author":"Palumbo","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"coi180059r31","doi-asserted-by":"publisher","first-page":"e431","DOI":"10.1016\/S2352-3026(17)30140-0","article-title":"Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial.","volume":"4","author":"Holstein","year":"2017","journal-title":"Lancet Haematol"},{"issue":"19","key":"coi180059r32","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma.","volume":"366","author":"McCarthy","year":"2012","journal-title":"N Engl J Med"},{"issue":"19","key":"coi180059r33","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.","volume":"366","author":"Attal","year":"2012","journal-title":"N Engl J Med"},{"issue":"10","key":"coi180059r34","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma.","volume":"371","author":"Palumbo","year":"2014","journal-title":"N Engl J Med"},{"issue":"16","key":"coi180059r35","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/S1470-2045(15)00389-7","article-title":"Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.","volume":"16","author":"Gay","year":"2015","journal-title":"Lancet Oncol"},{"key":"coi180059r36","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V130.Suppl_1.901.901","article-title":"Long term outcome of lenalidomide-dexamethasone (Rd) vs melphalan-lenalidomide-prednisone (MPR) vs cyclophosphamide-prednisone-lenalidomide (CPR) as induction followed by lenalidomide-prednisone (RP) vs lenalidomide (R) as maintenance in a community-based newly diagnosed myeloma population.","volume":"130","author":"Bringhen","year":"2017","journal-title":"Blood"},{"issue":"9","key":"coi180059r37","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1182\/blood-2015-08-662627","article-title":"Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma.","volume":"127","author":"Magarotto","year":"2016","journal-title":"Blood"},{"issue":"13","key":"coi180059r38","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1182\/blood-2011-11-374249","article-title":"IMWG consensus on maintenance therapy in multiple myeloma.","volume":"119","author":"Ludwig","year":"2012","journal-title":"Blood"},{"issue":"1","key":"coi180059r39","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1182\/asheducation-2011.1.197","article-title":"Posttransplantation maintenance therapy and optimal frontline therapy in myeloma.","volume":"2011","author":"Reece","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"14","key":"coi180059r40","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"coi180059r41","article-title":"Lenalidomide is a highly effective maintenance therapy in myeloma patients of all ages; results of the phase III Myeloma XI Study.","volume":"128","author":"Jackson","year":"2016","journal-title":"Blood"},{"issue":"20","key":"coi180059r42","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJM199005173222005","article-title":"Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy.","volume":"322","author":"Mandelli","year":"1990","journal-title":"N Engl J Med"},{"issue":"2","key":"coi180059r43","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1046\/j.1365-2141.1998.00795.x","article-title":"A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results.","volume":"102","author":"Cunningham","year":"1998","journal-title":"Br J Haematol"},{"issue":"11","key":"coi180059r44","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1023\/A:1026548226770","article-title":"Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients.","volume":"11","author":"Fritz","year":"2000","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"9758","key":"coi180059r45","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","article-title":"Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.","volume":"376","author":"Cavo","year":"2010","journal-title":"Lancet"},{"key":"coi180059r46","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V130.Suppl_1.744.744","article-title":"Impact of bortezomib- or lenalidomide-based induction treatment on high risk cytogenetic transplant-ineligible patients with newly diagnosed multiple myeloma enrolled in the Gimema-MM-03-05 and EMN01 trials.","volume":"130","author":"Larocca","year":"2017","journal-title":"Blood"},{"issue":"3","key":"coi180059r47","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/leu.2013.335","article-title":"Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients.","volume":"28","author":"Nooka","year":"2014","journal-title":"Leukemia"},{"issue":"11","key":"coi180059r48","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.364.364","article-title":"A multicenter prospective randomized study testing non-inferiority of thalidomide 100 mg\/day as compared with 400 mg\/day in patients with refractory\/relapsed multiple myeloma: first results of the final analysis of the IFM 01-02 study.","volume":"106","author":"Yakoub-Agha","year":"2005","journal-title":"Blood"},{"issue":"1","key":"coi180059r49","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1080\/10428194.2016.1177772","article-title":"A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation.","volume":"58","author":"Weisel","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"coi180059r50","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2147\/OTT","article-title":"Comparing efficacy and survivals of initial treatments for elderly patients with newly diagnosed multiple myeloma: a network meta-analysis of randomized controlled trials.","volume":"10","author":"Liu","year":"2016","journal-title":"Onco Targets Ther"},{"issue":"10068","key":"coi180059r51","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"coi180059r52","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3324\/haematol.11644","article-title":"Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma.","volume":"93","author":"Lokhorst","year":"2008","journal-title":"Haematologica"},{"issue":"22","key":"coi180059r53","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.537.537","article-title":"Health-related quality of life of patients with newly diagnosed multiple myeloma receiving any or lenalidomide maintenance after autologous stem cell transplant in the Connect MM disease registry.","volume":"128","author":"Abonour","year":"2016","journal-title":"Blood"},{"issue":"3","key":"coi180059r54","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S1470-2045(13)70609-0","article-title":"Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.","volume":"15","author":"Palumbo","year":"2014","journal-title":"Lancet Oncol"},{"key":"coi180059r23","unstructured":"Systematic reviews\/Meta-analyses\/HTA | Study Designs | The EQUATOR Network. UK EQUATOR Centre, Centre for Statistics in Medicine, NDORMS, University of Oxford. https:\/\/www.equator-network.org\/?post_type=eq_guidelines&eq_guidelines_study_design=systematic-reviews-and-meta-analyses&eq_guidelines_clinical_specialty=0&eq_guidelines_report_section=0&s=. Accessed February 23, 2018."}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2696339","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T00:16:34Z","timestamp":1661732194000},"score":1,"resource":{"primary":{"URL":"http:\/\/oncology.jamanetwork.com\/article.aspx?doi=10.1001\/jamaoncol.2018.2961"}},"subtitle":["A Systematic Review and Network Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2018,10,1]]},"references-count":54,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2018.2961","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10,1]]}}}